Callan Capital’s Cardiff Oncology CRDF Stock Holding History

Callan Capital’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$319K	Hold	101,575	–	–	0.02%	269
2024 Q4	$441K	Buy	101,575 +10,108	+11%	+$31.6K	0.03%	198
2024 Q3	$244K	Buy	91,467 +26,420	+41%	+$62.4K	0.02%	297
2024 Q2	$144K	Buy	65,047 +22,300	+52%	+$84K	0.01%	303
2024 Q1	$228K	Buy	42,747 +11,600	+37%	+$30.8K	0.02%	255
2023 Q4	$46.1K	Hold	31,147	–	–	﹤0.01%	232
2023 Q3	$43.3K	Buy	31,147 +17,560	+129%	+$29.6K	﹤0.01%	199
2023 Q2	$20K	Hold	13,587	–	–	﹤0.01%	182
2023 Q1	$22.4K	Hold	13,587	–	–	﹤0.01%	181
2022 Q4	$19K	Buy	+13,587	New	+$19.5K	﹤0.01%	184
2015 Q3	–	Sell	-157	Closed	-$115K	–	64
2015 Q2	$115K	Buy	+157	New	+$111K	0.02%	66

Other funds holding CRDF

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $26.6B AUM 22.97% 1-Year Est. Return

Callan Capital's CRDF Position: Q1 2025 in Review

Callan Capital held its Cardiff Oncology (CRDF) position steady in Q1 2025 at 101,575 shares worth $319K. The position accounts for 0.02% of the portfolio, ranked #269.

Callan Capital first reported a position in CRDF in Q2 2015 and has held it in 11 quarters since. The position peaked at $441K in Q4 2024. 116 funds tracked by Wall St. Rank hold CRDF as of Q1 2025.

Callan Capital held 101,575 shares of Cardiff Oncology worth $319K as of Q1 2025.
Callan Capital left its Cardiff Oncology share count unchanged in Q1 2025.
Cardiff Oncology made up 0.02% of Callan Capital's portfolio in Q1 2025, its #269 holding.
Callan Capital first reported a position in Cardiff Oncology in Q2 2015 and has held it in 11 quarters since.
Callan Capital's Cardiff Oncology position peaked at $441K in Q4 2024.
116 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2025.

Based on Callan Capital's 13F filing for Q1 2025, filed 29 Apr 2025.